EGFR and non-small cell lung carcinoma: Despite their initial effectiveness, the clinical success of DDP and EGFR-TKIs in NSCLC treatment is hampered by the development of acquired resistance in tumor cells (Mei et al., 2017; Liu M. et al., 2021).